亿帆医药：N-3C01注射液获临床试验批准

Core Viewpoint - The company Yifan Pharmaceutical (002019.SZ) has received approval from the National Medical Products Administration for clinical trials of its innovative macromolecule drug N-3C01, aimed at treating advanced solid tumors and non-muscle invasive bladder cancer (NMIBC) [1] Group 1 - Yifan Pharmaceutical's wholly-owned subsidiary Hefei Xinzhu Biotechnology Co., Ltd. has been granted a clinical trial approval notice for N-3C01 [1] - The clinical trials will focus on advanced solid tumors and NMIBC, indicating the company's commitment to oncology research [1]